[go: up one dir, main page]

AR007160A1 - ADHESION RECEPTOR ANTAGONIST COMPOUNDS, PROCEDURE FOR PREPARING THESE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM - Google Patents

ADHESION RECEPTOR ANTAGONIST COMPOUNDS, PROCEDURE FOR PREPARING THESE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

Info

Publication number
AR007160A1
AR007160A1 ARP970102054A ARP970102054A AR007160A1 AR 007160 A1 AR007160 A1 AR 007160A1 AR P970102054 A ARP970102054 A AR P970102054A AR P970102054 A ARP970102054 A AR P970102054A AR 007160 A1 AR007160 A1 AR 007160A1
Authority
AR
Argentina
Prior art keywords
compounds
preparing
pharmaceutical preparations
receptor antagonist
preparations containing
Prior art date
Application number
ARP970102054A
Other languages
Spanish (es)
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR007160A1 publication Critical patent/AR007160A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a los compuestos antagonistas del receptor de adhesión de fórmula (I), en la que R1, R2, R2, R3, U, V, W, X, Y, Ar, m, n, n, p y qtienen los significados indicados en la reivindicación 1, y a sus sales. También se refiere au n procedimiento para preparar estos compuestos, apreparaciones farmacéuticas que los contienen y al empleo de los mismos para preparar un medicamento. Los compuestos inhiben la unión de fibrinógeno alreceptor correspondiente, y se adecuan paracom batir las trombosis, osteoporosis, enfermedades tumorales, la apoplejía, el infarto de miocardio,las isquemias, las inflamaciones, la arterioesclerosis y las enfermedades osteolíticas.Refers to the adhesion receptor antagonist compounds of formula (I), in which R1, R2, R2, R3, U, V, W, X, Y, Ar, m, n, n, p and q have the indicated meanings in claim 1, and their salts. It also refers to a process for preparing these compounds, pharmaceutical preparations containing them and the use of them to prepare a medicament. The compounds inhibit the binding of fibrinogen to the corresponding receptor, and are suitable to combat thrombosis, osteoporosis, tumor diseases, stroke, myocardial infarction, ischemia, inflammation, arteriosclerosis and osteolytic diseases.

ARP970102054A 1996-05-17 1997-05-16 ADHESION RECEPTOR ANTAGONIST COMPOUNDS, PROCEDURE FOR PREPARING THESE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM AR007160A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19620041A DE19620041A1 (en) 1996-05-17 1996-05-17 Adhesion receptor antagonists

Publications (1)

Publication Number Publication Date
AR007160A1 true AR007160A1 (en) 1999-10-13

Family

ID=7794651

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102054A AR007160A1 (en) 1996-05-17 1997-05-16 ADHESION RECEPTOR ANTAGONIST COMPOUNDS, PROCEDURE FOR PREPARING THESE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

Country Status (5)

Country Link
AR (1) AR007160A1 (en)
AU (1) AU2957997A (en)
DE (1) DE19620041A1 (en)
WO (1) WO1997044333A1 (en)
ZA (1) ZA974234B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729488B2 (en) * 1996-08-29 2001-02-01 Merck & Co., Inc. Compositions and methods for administering integrin receptor antagonists
PL341984A1 (en) 1998-01-28 2001-05-07 Shionogi & Co Novel tricycle compounds
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
EP1054871A2 (en) * 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003531141A (en) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド Enamine derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (en) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド 3-position substituted isoquinolin-1-yl derivative
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2002313633B2 (en) * 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
AU2003276043A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
JP2006516144A (en) 2002-12-20 2006-06-22 ファルマシア・コーポレーション Thiazole compounds as integrin receptor antagonist derivatives
US20050043344A1 (en) * 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
ES2887054T3 (en) * 2003-04-11 2021-12-21 Ptc Therapeutics Inc 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and disease treatment
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
EP1893591A1 (en) * 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
EP1907383A1 (en) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
IN2014CN04406A (en) 2006-03-30 2015-09-04 Ptc Therapeutics Inc
PT3357911T (en) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Compounds
US8362050B2 (en) * 2008-06-24 2013-01-29 Irm Llc Compounds and methods for modulating G protein-coupled receptors
NO2686520T3 (en) 2011-06-06 2018-03-17
WO2012170442A1 (en) 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CR20160222U (en) 2013-11-15 2016-08-26 Akebia Therapeutics Inc SOLID FORMS OF ACID {[- (3- CHLOROPHENYL) -3- HYDROXIPIRIDIN -2-CARBONIL] AMINO} ACETIC, COMPOSITIONS, AND USES OF THE SAME
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
UA123308C2 (en) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. COMPOSITIONS AND METHODS FOR TREATMENT OF ANEMIA
CN108348527A (en) 2015-10-30 2018-07-31 Ptc医疗公司 Method for treating epilepsy
JP7440989B2 (en) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド Method for preparing 2-[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
GB202209228D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935523A (en) * 1961-06-17 1963-08-28 Acraf New sulphamido-oxadiazoles
JPS51143669A (en) * 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
JPS52272A (en) * 1975-10-17 1977-01-05 Takeda Chem Ind Ltd Process for preparing 1,2,4-oxadiazole derivatives
US4135910A (en) * 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents

Also Published As

Publication number Publication date
WO1997044333A1 (en) 1997-11-27
DE19620041A1 (en) 1998-01-29
ZA974234B (en) 1997-12-11
AU2957997A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
AR007160A1 (en) ADHESION RECEPTOR ANTAGONIST COMPOUNDS, PROCEDURE FOR PREPARING THESE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
MX9504630A (en) NEW DERIVATIVES OF OXAZOLIDINONE, ANTAGONIST OF THE ADHESION RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR003121A1 (en) ADHESION RECEPTOR ANTAGONISTS, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE TO PREPARE MEDICINES AND FIGHT DISEASES
LU91145I2 (en) FIROCOXIB optionally in the form of a pharmaceutically acceptable salt (PREVICOX).
AR062931A2 (en) COMPOUNDS THAT LINK TO AND ACTIVATE A THROMBOPOYETIN RECEPTOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE FOR THE PREPARATION OF MEDICINES
MX9706069A (en) Novel dipeptide amidines as thrombin inhibitors.
CO4930259A1 (en) DERIVATIVES 6,6-HETEROBICICLICOS SUBSTITUTED AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR001332A1 (en) New tachykinin antagonist compounds, process to obtain them and pharmaceutical compositions containing them.
AR006273A1 (en) NITROGENATED HETERO-CYCLE COMPOUNDS OF RINGS OF 5 MEMBERS AS NEW INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS, PROCEDURE FOR THE PREPARATION, USE OF SUCH MEDICINES, PREPARATION OF A MEDICINAL PRODUCT, AND
NO301419B1 (en) 2-oxo-5-oxazolidine methyl compounds, pharmaceutical compositions containing them, and their use in the manufacture of pharmaceuticals
ES2060951T3 (en) AZAINDENOS.
HN1998000157A (en) PROSTAGLANDIN AGONISTS
ES2110761T3 (en) PIRROLIDIN-3-IL-ALKYL-PIPERIDINES SUBSTITUTED USEFUL AS AN TAGIQUININE ANTAGONISTS.
ES2183332T3 (en) AROMATIC BICYCLE AMINO ACIDS.
CO4650038A1 (en) SUBSTITUTED INDAZOL DERIVATIVES AND RELATED COMPOUNDS
MX9305947A (en) ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9306311A (en) ANTAGONIST COMPOUNDS OF THE 5-HT4 RECEPTOR, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR002245A1 (en) ANTAGONISTS OF THE ADHESION RECEPTOR, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM AND THE USE OF THE SAME TO PREPARE MEDICINES.
TR199701645A2 (en) Vitronectin receptor antagonists, their manufacture and use
ES2192621T3 (en) SALTS OF QUINOLEINE DERIVATIVES AS AN NG3 ANTAGONISTS.
MX9304424A (en) BENZIMIDAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
UY26988A1 (en) NEW INDOLINONES REPLACED, ITS PREPARATION AND ITS USE AS MEDICINES.
EP0888345A4 (en) SIGMA-2 RECEPTORS FOR USE AS BIOMARKERS OF TUMOR CELL PROLIFERATION
MX9300306A (en) BENZMIDAZOLES MEDICINES CONTAINING THESE COMPOUNDS AND PROCEDURE FOR THEIR PREPARATION.
ES2043943T3 (en) PROCEDURE FOR THE PREPARATION OF COMPOUNDS WITH CENTRAL ANALGESIC ACTIVITY.